Navigation Links
Vaccine patent portfolio licensed from UK Ministry of Defence
Date:2/19/2009

TORONTO, Feb. 19 /PRNewswire/ - Defyrus Inc. today announced the signing an exclusive, worldwide license to a patent portfolio created by the United Kingdom's Defence Science and Technology Laboratory (Dstl) and licensed by Ploughshare Innovation Ltd, Dstl's commercialization company. These patents form the intellectual property foundation of the Company's vaccine product development programs. Defyrus and Ploughshare Innovation Ltd plan to expand their commercial interaction in 2009 to include preclinical safety and efficacy studies as part of the Company's vaccine development program. The commercial terms of the license were not disclosed.

The licensed technology of 27 issued & pending international patents, describes the production of multi-valent vaccines for the treatment of alpha-viral infections resulting from bioterrorism or endemic disease. These highly infectious, mosquito-borne encephalitis viruses pose a serious risk to people and livestock for which no vaccine or therapy exists.

"Dstl has pioneered the investigation of effective medical countermeasures (e.g. vaccines and drugs) for the treatment of a number of important biological diseases that are potential biological warfare threats. Their unique approach to vaccine development and compelling animal efficacy data for viral encephalitis made this license attractive" commented Dr. Jeffrey D. Turner, President & CEO of Defyrus, "We see tremendous synergy in levering investor capital with successful Government R&D programs to drive cost-effective, rapid drug development forward. Improving our capability to respond to viral threats from endemic disease or biological warfare is our mission and represents a significant contribution to protecting the international community from dangerous pathogens".

"Defyrus' business model has the hallmark of a true public-private collaboration. In licensing Dstl's technology to Defyrus, whose management team have a proven track record in vaccine development, Ploughshare expects that Dstl's pioneering work can be rapidly translated into vaccines that are available for both the public health markets in the developing world, as well as the North American and European defence markets" stated Andy Tulloch, Chief Executive Officer Ploughshare Innovations. "We look forward to expanding our interactions with Defyrus in the years to come" added Dr. David Harris, Head of Technology Transfer at Dstl.

About Defyrus

Defyrus is a private, life sciences biodefence company that collaborates with domestic and international military R&D partners to develop a range of therapeutics as medical countermeasures for civilians and military personnel. www.defyrus.com

About Ploughshare Innovations & Dstl

Ploughshare is wholly owned by the United Kingdom's Secretary of State for Defence and facilitates the commercialization of defence technologies arising from Dstl. Dstl is an agency of the UK's Ministry of Defence (MoD), existing to supply the very best, impartial, scientific and technical research and advice to the MoD and other Government Departments. Dstl houses one of the largest groups of scientists and engineers (3,500-strong work force) in public service in the UK and supports procurement decisions, defence policy-making and operations. www.ploughshareinnovations.com & www.dstl.gov.uk


'/>"/>
SOURCE Defyrus Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
Breaking Medicine Technology: